Nasdaq
$25.02▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.56BShares out 62.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
21- 3d agoAfter-hours26.10.22 05:42144Ownership#●●●#●●●
Stoke Therapeutics, Inc.
Director Edward M. Kaye of Stoke Therapeutics has filed a Form 144 with the SEC regarding a proposed sale of company securities. This filing serves as a standard notification of an insider's plan to dispose of shares.…more
$25.02+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.2After-hours26.10.03 06:374Ownership
Stoke Therapeutics, Inc.
Insider Allan Jonathan of Stoke Therapeutics, Inc. filed a Form 4 on October 2, 2026, reporting changes in beneficial ownership of securities. This filing serves as a standard disclosure of insider equity transactions.…more
$25.02+0.00%vs prev closeView filingShare - 10.2After-hours26.10.03 06:354Ownership
Stoke Therapeutics, Inc.
Insider Barry Ticho of Stoke Therapeutics, Inc. filed a report regarding their beneficial ownership of securities as of October 1, 2026. This filing serves as a standard disclosure of insider equity holdings.…more
$25.02+0.00%vs prev closeView filingShare
20 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.12Pre-market26.10.12 21:07#●●●#●●●#●●●
Stoke Therapeutics Presents Data for ADOA Candidate STK-002
Stoke Therapeutics presented preclinical and Phase 1 data for its ADOA treatment candidate, STK-002, at the AAO 2026 Annual Meeting. The company is currently conducting the OSPREY Phase 1 study, with initial safety and efficacy results expected in the first half of 2027.…more
$25.02+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.5Pre-market26.10.05 20:10
●●●●●●●● ●●●●● ●●●●●●
Stoke Therapeutics announced that the FDA is willing to accept its planned Phase 3 cognition and behavior analysis for Zorevunersen in Dravet syndrome. This agreement provides a clearer regulatory path for the company's clinical development program.…more
$25.02+0.00%vs prev closeShareBenzinga - 9.4Pre-market26.09.04 17:00
●●●●●●●● ●●●●● ●●●●●●
Stoke Therapeutics and Biogen presented over five years of clinical data showing durable seizure reduction and cognitive improvements for their Dravet syndrome candidate, zorevunersen. While the results support the drug's potential as a disease-modifying treatment, further clinical development is required.…more
$25.02+0.00%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report